This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Moxidectin

**Dosage Form; Route:** Tablet; oral

**Recommended Studies:** Two studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 2 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population  
   **Additional comments:** Consider using a parallel study design due to moxidectin’s long half-life. For long half-life drug products with low intra-subject variability in distribution and clearance, an area under the plasma concentration time curve (AUC) truncated to 72 hours may be used in place of AUC_{0-t} or AUC_{0-\infty}. For either a crossover or parallel study, sample collection time should be adequate to ensure completion of gastrointestinal transit of the drug product and absorption of the drug substance. Collect sufficient blood samples in the bioequivalence studies to adequately characterize peak drug concentration and time to reach peak drug concentration.

2. **Type of study:** Fed  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 2 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population  
   **Additional comments:** See comments above

**Analyte to measure (in appropriate biological fluid):** Moxidectin in plasma

**Bioequivalence based on (90% CI):** Moxidectin

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units for each of the test and reference
products. Specifications will be determined upon review of the abbreviated new drug application.